Australian biopharmaceutical company CSL Ltd has entered an exclusive licensing agreement with Eli Lilly and Company, granting the US pharmaceutical giant rights to develop and commercialize CSL's clazakizumab treatment for heart and kidney disease. The deal sent CSL shares climbing as much as 2% to A$154.21, contributing to a 0.4% rise in the broader market.

Under the agreement, CSL will receive an upfront payment of $100 million and is eligible for additional clinical and commercial milestone payments, along with royalties on global sales. The licensing arrangement represents a significant strategic move for CSL, which has been working to strengthen its cardiovascular and renal disease pipeline. The positive market reaction helped CSL shares recover some ground after logging steep losses last week when the company reported weak first-half earnings and announced changes in its top leadership.

This partnership with Eli Lilly provides CSL with substantial near-term cash flow while maintaining potential long-term upside through milestone payments and royalties. For Eli Lilly, the deal adds another promising therapeutic candidate to its expanding portfolio of treatments for chronic diseases. The collaboration underscores the growing interest in clazakizumab as a potential breakthrough treatment for cardiovascular and renal conditions, with both companies positioning themselves to capitalize on what could become a significant market opportunity.